GENELUX Corp

Nasdaq:GNLX

Pharmaceutical Preparations·WESTLAKE VILLAGE, CA

CEO

Zindrick Thomas

Summary Financials

Revenue

$170,000

-98.5% YoY

FY 2024

Adj. EBITDA

-$23.7M

-13921.2% margin

FY 2024

Net Income

-$28.3M

-16645.3% margin

FY 2024

EPS (Diluted)

-$1.16

FY 2024

Stock Price

$2.79

-0.4%

2026-03-10

52W Range

$1.99 – $8.54

P/E Ratio

-2.4x

Market Cap

$106.2M

Cash

$9.4M

FY 2024

Total Debt

$900,000

FY 2024

Net Cash

$8.5M

FY 2024

Enterprise Value

$97.6M

Debt / EBITDA

0.4x

FY 2024

EV / EBITDA

-4.1x

Employees

—

Revenue

$170,000

-98.5% YoY

FY 2024

Adj. EBITDA

-$23.7M

-13921.2% margin

FY 2024

Net Income

-$28.3M

-16645.3% margin

FY 2024

EPS (Diluted)

-$1.16

FY 2024

Stock Price

$2.79

-0.4%

2026-03-10

52W Range

$1.99 – $8.54

P/E Ratio

-2.4x

Market Cap

$106.2M

Cash

$9.4M

FY 2024

Total Debt

$900,000

FY 2024

Net Cash

$8.5M

FY 2024

Enterprise Value

$97.6M

Debt / EBITDA

0.4x

FY 2024

EV / EBITDA

-4.1x

Employees

—